Mehta Vimal 4

What Happened Vimal Mehta, CEO, President and a director of BioXcel Therapeutics (BTAI), had 219 restricted stock units (RSUs) convert into 219 shares of common stock on June 15, 2026. The Form 4 shows an acquisition entry for 219 shares via conversion of a derivative security and a corresponding disposition entry at $0.00 for the derivative (i.e., the RSUs ceased to exist). No cash was paid or received in this transaction — this was a vesting/conversion event, not an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-15; Form 4 filed 2026-06-17 (timely filing).
• Reported entries: +219 shares acquired via conversion of derivative (code M); 219 derivative units disposed at $0.00.
• Price / value: No cash consideration reported; acquisition price N/A, disposition price $0.00.
• Shares owned after transaction: Not specified in this filing.
• Notable footnotes:
  • F1: Each RSU converts to one share of common stock when vested.
  • F3: The RSUs were part of a 3,500-RSU grant (granted 3/15/2023) that vests 25% after one year and 6.25% each quarter thereafter.
  • F2: Some securities are held of record by BioXcel LLC; Mehta may be deemed to have beneficial ownership of holdings held by that entity but disclaims ownership except to the extent of any pecuniary interest.

Context This appears to be a routine scheduled vesting installment from a previously disclosed 3,500-RSU grant (6.25% of 3,500 ≈ 219), not a sale or purchase. For retail investors, such RSU conversions increase the insider’s reported share count but do not by themselves signal a buy or sell intent.